Theravance secures U.S. approval for Yupelri in COPD

Theravance Biopharma Inc. (NASDAQ:TBPH) and partner Mylan N.V. (NASDAQ:MYL) said FDA approved Yupelri revefenacin

Read the full 147 word article

User Sign In